The identification of five distinct HFpEF clusters confirms the heterogeneity of the condition and supports individualized drug therapy and tailored trial designs.
Five distinct clusters of HFpEF patients were identified that differed in clinical characteristics, heart failure drug therapy and prognosis. These results confirm the heterogeneity of HFpEF and form a basis for tailoring trial design to individualized drug therapy in HFpEF patients.
Uijl et al. (Mon,) studied this question.